Skip to main content

CORRECTION article

Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1505626

Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review

Provisionally accepted
C.A.M. van Riel C.A.M. van Riel 1,2*C.A.J. Michielsens C.A.J. Michielsens 1,2M.E. van Muijen M.E. van Muijen 3,4L.S. van der Schoot L.S. van der Schoot 1,2J.M.P.A. van den Reek J.M.P.A. van den Reek 1,2E.M.G.J. de Jong E.M.G.J. de Jong 1,2,5
  • 1 Radboud University Medical Centre, Nijmegen, Netherlands
  • 2 Department of Dermatology, Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands
  • 3 Maastricht University Medical Centre, Maastricht, Limburg, Netherlands
  • 4 Department of Dermatology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands, Netherlands
  • 5 Radboud University, Nijmegen, Gelderland, Netherlands

This article is a correction to:

  1. Dose reduction of biologics in patients with plaque psoriasis: a review

    1. Read original article

The final, formatted version of the article will be published soon.

    Corrigendum on: van Riel CAM, Michielsens CAJ, van Muijen ME, van der Schoot LS, van den Reek JMPA and de Jong EMGJ (2024), Dose reduction of biologics in patients with plaque psoriasis: a review. Front. Pharmacol. 15:1369805. doi: 10.3389/fphar.2024.1369805 In the published article, there was an error. The symbol '≤', in the phrase "… biologic use for ≤6 months,…" was accidentally added in the corresponding sentence (see below). This should be the symbol '≥'.A correction has been made to Discussion, Paragraph 5. This sentence previously stated: "Considering the studies on DR strategies, the eligibility criteria for DR mainly included biologic use for ≤6 months, a stable low disease activity from ≥6 months to ≥ 1 year, determined by an absolute or relative PASI (PASI ≤3/≤5/ PASI 75-100) and/or DLQI ≤3/≤5, or BSA ≤1/≤2, or PGA ≤1/0-2 during a period ranging from 12 weeks to ≥ 1 year (Atalay et al., 2021;Aubert et al., 2022;Atalay et al., 2022b;van der Schoot et al., 2022b;Di Altobrando et al., 2022;van Muijen et al., 2022;Herranz-Pinto et al., 2023)."The corrected sentence appears below: "Considering the studies on DR strategies, the eligibility criteria for DR mainly included biologic use for ≥6 months, a stable low disease activity from ≥6 months to ≥1 year, determined by an absolute or relative PASI (PASI ≤3/≤5/ PASI 75-100) and/or DLQI ≤3/≤5, or BSA ≤1/≤2, or PGA ≤1/0-2 during a period ranging from 12 weeks to ≥1 year (Atalay et al., 2021;Aubert et al., 2022;Atalay et al., 2022b;van der Schoot et al., 2022b;Di Altobrando et al., 2022;van Muijen et al., 2022;Herranz-Pinto et al., 2023)."The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

    Keywords: Psoriasis, dose reduction, Dose Tapering, clinical practice, implementation, biologics, biologicals, (cost-)effectiveness

    Received: 03 Oct 2024; Accepted: 07 Oct 2024.

    Copyright: © 2024 van Riel, Michielsens, van Muijen, van der Schoot, van den Reek and de Jong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: C.A.M. van Riel, Radboud University Medical Centre, Nijmegen, Netherlands

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.